ArticleCureus2025
Pravastatin Mitigates Hypertension, Proteinuria, and Fetal Growth Restriction in an L-NG-Nitro Arginine Methyl Ester (L-NAME)-Induced Rat Model of Preeclampsia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPreeclampsia is a common pregnancy complication characterized by the abrupt onset of hypertension and proteinuria occurring after the midpoint of gestation. If left untreated, it can severely threaten the health of both the mother and the infant. This study aimed to evaluate the potential therapeutic effects of pravastatin in a rat model of preeclampsia. The study examined the efficacy of its ability to modulate key clinical and biochemical parameters, including blood pressure, proteinuria, nitric oxide concentrations, and the weights of the fetus and placenta.
methodsA total of 21 pregnant Wistar rats were divided into three groups: (1) a normal pregnant group; (2) a preeclamptic group (induced by a subcutaneous injection of L-NG-Nitro arginine methyl ester (L-NAME)); and (3) a preeclamptic group treated with pravastatin. The effects of pravastatin were evaluated on blood pressure and proteinuria, as well as its impact on endothelial function (serum nitric oxide) and birth outcomes (fetal and placental weights).
resultsThe results showed that L-NAME successfully created a preeclampsia model, which was marked by a notable rise in blood pressure and protein levels in urine, as well as a decrease in the weights of the fetus and placenta. The L-NAME group had reduced serum levels of nitric oxide, but the difference was not statistically significant. Conversely, pravastatin therapy entirely mitigated the detrimental effects of L-NAME. It resulted in significant reductions in blood pressure and proteinuria, along with increases in fetal and placental weights, plus an insignificant increase in nitric oxide levels.
conclusionPravastatin demonstrates significant promise as a therapeutic intervention that can mitigate pathophysiological changes of an L-NAME-induced preeclampsia, such as hypertension, proteinuria, and diminished fetal and placental weights. Although the increase in serum nitric oxide levels did not reach statistical significance, the observed upward trend may reflect a partial restoration of endothelial function, which is typically impaired in this model. This suggests that pravastatin may exert a protective effect on the endothelium, at least in part, through modulation of NO pathways. Additional research, including clinical trials, is necessary to ascertain safety, optimal dosage, and long-term effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.